Olink Holding AB (publ) (NASDAQ:OLK – Get Rating) is scheduled to issue its quarterly earnings data before the market opens on Thursday, August 11th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter. Olink Holding AB (publ) has set its FY 2022 guidance at EPS.Parties interested in listening to the company’s conference call can do so using this link.
Olink Holding AB (publ) (NASDAQ:OLK – Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. The company had revenue of $22.68 million for the quarter, compared to analyst estimates of $20.14 million. Olink Holding AB (publ) had a negative return on equity of 7.46% and a negative net margin of 34.81%. During the same quarter in the previous year, the firm earned ($0.48) earnings per share. On average, analysts expect Olink Holding AB (publ) to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Olink Holding AB (publ) Trading Up 2.8 %
OLK stock opened at $15.25 on Thursday. The company has a market cap of $1.82 billion, a P/E ratio of -49.19 and a beta of 0.38. Olink Holding AB has a twelve month low of $8.39 and a twelve month high of $38.01. The company has a quick ratio of 5.15, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The business has a fifty day moving average of $13.27 and a 200-day moving average of $14.77.
Institutional Investors Weigh In On Olink Holding AB (publ)
Analyst Upgrades and Downgrades
Separately, The Goldman Sachs Group dropped their price objective on Olink Holding AB (publ) from $20.00 to $16.00 and set a “neutral” rating for the company in a report on Thursday, July 14th.
About Olink Holding AB (publ)
Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on.
- Get a free copy of the StockNews.com research report on Olink Holding AB (publ) (OLK)
- Two High-Yield Deep-Values You Shouldn’t Ignore
- Is Starbucks Shooting For The Moon?
- PayPal Continues To Struggle As Competition Increases
- Proposed Tesla Stock Split Drives EV Market Higher
- Caterpillar Falls To Strong Support Near Bottom Of Range
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Olink Holding AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olink Holding AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.